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I
n this issue of Science & Practice Perspectives, a dia-
logue between researcher Dr. Linda Chang and clini-
cal psychiatrist Dr. Paul Linde provides a prime exam-
ple of how bringing together a researcher’s conceptual
framework and a skillful clinician’s understanding of clin-
ical nuance stimulates and enriches both. Together, Chang
and Linde consider whether the results to date from non-
invasive brain imaging studies might support his use of
certain medications with methamphetamine abusers.
Ultimately, they conclude that the findings appear con-
sistent with Linde’s use of some of the medications, raise
concerns about others, and can’t strictly endorse any. Along
the way, the colloquy identifies two good opportunities for
research studies and appropriate messages to give patients
based on imaging studies.
If Chang and Linde’s discussion exemplifies the depth
of integration now occurring between research and clini-
cal practice in drug abuse, the overall contents of the jour-
nal indicate its breadth. Topics range from clinical inter-
ventions to the challenges of making organizational changes
and of laying a foundation for systemic change. The research-
practice engagement evident in Perspectives reflects a broad
maturity of collaborative solution-seeking in the treatment
of drug abuse. To cite some examples:
• NIDA’s Clinical Trials Network has now published the
results of studies of motivational interviewing, contin-
gency management, and opiate detoxification with the
medication combination of buprenorphine and naloxone.
Although these studies proved their hypotheses, an equally
important outcome was that researchers and community
clinicians jointly planned and accomplished projects that
served both of their learning agendas.
• The Blending Initiative—a collaboration between NIDA,
the Substance Abuse and Mental Health Services
Administration, and the Addiction Treatment Technology
Centers—has released four evidence-based, validated
tools for staff training. They cover the use of buprenor-
phine for opiate withdrawal and for longer term treat-
ment, and offer guidance on administering and inter-
preting the Addiction Severity Index.
There always will be some degree of divergence between
research and clinical practice in the treatment of substance
abuse, because the two enterprises have different natures.
Communication across this gap is critical to achieve the
common goal of reducing drug abuse and addiction, and